Teva Pharmaceutical Industries' drug Austedo should reach sales of $2.5 billion by 2027, chief executive Richard Francis said on Thursday. Austedo is Teva's branded treatment for Huntington's ...

Austedo (deutetrabenazine) is a brand-name drug that’s prescribed for certain movement disorders in adults. It comes as an oral tablet, Austedo, and an extended-release oral tablet, Austedo XR.

No-moat Teva reported second-quarter earnings that were slightly ahead of our expectations. Total sales were up 2.4% year over year, driven by strong performance from Teva’s key innovative ...

(RTTNews) - Teva Pharmaceuticals announced results from a post hoc analysis of a long-term, 3-year open-label extension (OLE) study examining efficacy and safety endpoints for the use of Austedo ...

The company said the approximately 3-year study showed that treatment with AUSTEDO had a safety and tolerability profile comparable with the First-HD randomized, double-blind, ...